Displaying all 3 publications

Abstract:
Sort:
  1. Fulltext Effect and safety of gemtuzumab ozogamicin for the treatment of patients with acute myeloid leukaemia: a systematic review protocol
    Muhamad NA, Mohd Dali NS, Mohd Yacob A, Kassim MSA, Lodz NA, Abdul Wahid SF, et al.
    BMJ Open, 2020 Jun 15;10(6):e032503.
    PMID: 32540885 DOI: 10.1136/bmjopen-2019-032503
    INTRODUCTION: Acute myeloid leukaemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells or platelets. Gemtuzumab ozogamicin (GO) holds promise as a new agent that also could be efficacious in newly diagnosed AML with acceptable toxicity. This paper describes the design of a protocol to conduct a systematic review of published studies assessing GO for the treatment of AML.

    METHOD AND ANALYSIS: We will conduct a systematic review of randomised controlled trials that investigate the effect and safety of GO for the treatment of patients with AML. We will search for any eligible articles from selected electronic databases. We will follow the Preferred Reporting Items for Systematic reviews and Meta-Analysis for study selection and reporting. We will use The Cochrane Handbook for Systematic Reviews of Interventions and Meta-Analysis as guidance to select eligible studies. All data will be extracted using a standardised data extraction form.

    ETHICS AND DISSEMINATION: There was no patient involved in this study, therefore no ethical consideration is needed. The findings of this study will be disseminated in a peer-reviewed journal and any relevant conference presentation.

    PROSPERO REGISTRATION NUMBER: CRD42019123286.

  2. Fulltext Prevalence of caregiver hesitancy for vaccinations in children and its associated factors: A systematic review and meta-analysis
    Maamor NH, Muhamad NA, Mohd Dali NS, Leman FN, Rosli IA, Tengku Bahrudin Shah TPN, et al.
    PLoS One, 2024;19(10):e0302379.
    PMID: 39446774 DOI: 10.1371/journal.pone.0302379
    This review aimed to systematically compare and pool the prevalence of all the known evidence on caregiver hesitancy and to describe the factors influencing vaccine hesitancy among caregiver worldwide such as COVID-19, MMR, Influenza, HPV and others. We searched article from few electronic databases (PubMed, CENTRAL, ProQuest, and Web of Science) from inception to August 2023 using specific keywords for example caregiver, parents, prevalence, factor, hesitancy, and others. We included population-based studies that reported the prevalence of caregiver hesitancy. We used random-effects meta-analyses for pool prevalence estimates of caregiver hesitancy. A total of 765 studies met our inclusion criteria, containing data on 38,210,589 caregivers from seven regions across the globe. Overall or pool prevalence of vaccine hesitancy among caregiver is 25.0% (95% CI: 0.22-0.27, I2 = 99.91%, p = 0.001). Based on the evidence gathered, vaccine hesitancy was found to be religious sentiments, personal beliefs, perceived safety concerns, and a desire for more information from healthcare providers, along with factors related to availability, accessibility, affordability, and acceptability of vaccinations. Vaccine safety and efficiency have been identified as the main factor for caregiver vaccine hesitancy globally with a prevalence of 91.4%. Trial registration PROSPERO registration number: CRD42022331629. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022331629.
  3. Fulltext Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma
    Tan LP, Tan GW, Sivanesan VM, Goh SL, Ng XJ, Lim CS, et al.
    Int J Cancer, 2020 04 15;146(8):2336-2347.
    PMID: 31469434 DOI: 10.1002/ijc.32656
    Nasopharyngeal carcinoma (NPC) is originated from the epithelial cells of nasopharynx, Epstein-Barr virus (EBV)-associated and has the highest incidence and mortality rates in Southeast Asia. Late presentation is a common issue and early detection could be the key to reduce the disease burden. Sensitivity of plasma EBV DNA, an established NPC biomarker, for Stage I NPC is controversial. Most newly reported NPC biomarkers have neither been externally validated nor compared to the established ones. This causes difficulty in planning for cost-effective early detection strategies. Our study systematically evaluated six established and four new biomarkers in NPC cases, population controls and hospital controls. We showed that BamHI-W 76 bp remains the most sensitive plasma biomarker, with 96.7% (29/30), 96.7% (58/60) and 97.4% (226/232) sensitivity to detect Stage I, early stage and all NPC, respectively. Its specificity was 94.2% (113/120) against population controls and 90.4% (113/125) against hospital controls. Diagnostic accuracy of BamHI-W 121 bp and ebv-miR-BART7-3p were validated. Hsa-miR-29a-3p and hsa-miR-103a-3p were not, possibly due to lower number of advanced stage NPC cases included in this subset. Decision tree modeling suggested that combination of BamHI-W 76 bp and VCA IgA or EA IgG may increase the specificity or sensitivity to detect NPC. EBNA1 99 bp could identify NPC patients with poor prognosis in early and advanced stage NPC. Our findings provided evidence for improvement in NPC screening strategies, covering considerations of opportunistic screening, combining biomarkers to increase sensitivity or specificity and testing biomarkers from single sampled specimen to avoid logistic problems of resampling.
Related Terms
    Try searching for something
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links